If approved, crinecerfont will be the first new treatment option for CAH in 70 years and represents a novel therapeutic approach, offering a new treatment method for this rare and severe endocrine disorder.

Lonapegsomatropin (Skytrofa) received FDA approval on August 25, 2021.

Vivani Medical, Inc., a pioneering company in biopharmaceuticals, revealed plans to commence the inaugural clinical trial for the NPM-115 initiative in Australia.

The U.S. Food and Drug Administration (FDA) approved Difelikefalin on August 23, 2021, for the treatment of moderate-to-severe pruritus (itching) associated with chronic kidney disease in adults undergoing hemodialysis (HD).

Radioligand therapy (RLT), as a part of radiopharmaceuticals, delivers high-energy radiation directly to cancer cells by targeting their structural or biochemical mutations.

The U.S. Food and Drug Administration (FDA) approved Belzutifan on August 13, 2021, for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC).

Pfizer have chosen the preferred once-daily modified release form of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.

The U.S. Food and Drug Administration (FDA) approved Avalglucosidase alfa for the treatment of late-onset Pompe disease (LOPD) on August 6, 2021.

Jul 16th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

The U.S. Food and Drug Administration (FDA) approved Anifrolumab for the treatment of moderate to severe systemic lupus erythematosus (SLE) in adults on July 30, 2021.

This submission seeks regulatory approval through the Therapeutic Goods Administration (TGA)’s Clinical Trial Notification scheme to initiate a first-in-human Phase 1 clinical trial for SAT-3247.

The U.S. Food and Drug Administration (FDA) approved Twyneo for use in the treatment of acne vulgaris on July 26, 2021.